SCHEMBL4672159

SCHEMBL4672159

O=C(Cc1nc(S(=O)(=O)c2ccc(F)cc2)cs1)C(=O)c1nc[nH]n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.37
KCNH2 Q12809 2/20 0.37
LOXL2 Q9Y4K0 7/20 0.36
AKR1B1 P15121 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LOXL3 P58215 1/20 0.33
ULK1 O75385 1/20 0.33
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
MMP12 P39900 1/20 0.32
MMP13 P45452 1/20 0.32
MMP14 P50281 1/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
BCHE P06276 1/20 0.32
VDR P11473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673943 0.90 LOXL2 (0.41) LOXL2AKR1B1LOXL3ALDH1A1
SCHEMBL4672029 0.89 HTT (0.37) LOXL2AKR1B1MEN1KMT2ALOXL3
SCHEMBL4676317 0.83 LOXL2 (0.36) HTR2AKCNH2LOXL2AKR1B1MEN1
SCHEMBL4677358 0.81 KMT2A (0.39) HTR2AKCNH2AKR1B1MEN1KMT2A
SCHEMBL4674792 0.80 LOX (0.33) HTR2AKCNH2LOXL2AKR1B1MEN1
SCHEMBL4672336 0.80 HDAC6 (0.39) MEN1KMT2AALDH1A1MAPTBCHE
SCHEMBL4674440 0.79 HTR2A (0.34) HTR2AKCNH2LOXL2AKR1B1MEN1
SCHEMBL4671735 0.77 MMP1 (0.35) HTR2AKCNH2AKR1B1MEN1KMT2A
SCHEMBL4671745 0.77 MMP1 (0.33) HTR2AKCNH2AKR1B1MEN1KMT2A
SCHEMBL4672013 0.77 MMP1 (0.37) HTR2AKCNH2AKR1B1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HTR2A 441/4885KCNH2 3174/4885LOXL2 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.